Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takako Inoue

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|August 23, 2023
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapiesNaoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, et al.
Plos One|November 15, 2022
Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational studyTatsuya Nishikawa, Takako Inoue, Tomoyuki Otsuka, et al.
Lung Cancer (Amsterdam, Netherlands)|December 5, 2020
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunctionKei Kunimasa, Toru Oka, Satoshi Hara, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 19, 2021
Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infectionTakako Inoue, Yui Funatsu, Masaya Ohnishi, et al.
Cancer Science|February 25, 2024
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION studyMasahiro Morise, Terufumi Kato, Shingo Matsumoto, et al.
Plos One|February 14, 2022
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis BYoshihito Nagura, Kentaro Matsuura, Etsuko Iio, et al.
Thoracic Cancer|September 13, 2022
Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective studyKei Kunimasa, Naotoshi Sugimoto, Takahisa Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 30, 2020
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitisMasanori Furukawa, Kei Moriya, Jiro Nakayama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2022
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivationTakanori Suzuki, Kentaro Matsuura, Kenji Urakabe, et al.
Journal of Gastroenterology and Hepatology|June 29, 2024
Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysisTakanori Suzuki, Kentaro Matsuura, Yuta Suzuki, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|August 23, 2023
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapiesNaoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, et al.
Plos One|November 15, 2022
Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational studyTatsuya Nishikawa, Takako Inoue, Tomoyuki Otsuka, et al.
Lung Cancer (Amsterdam, Netherlands)|December 5, 2020
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunctionKei Kunimasa, Toru Oka, Satoshi Hara, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 19, 2021
Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infectionTakako Inoue, Yui Funatsu, Masaya Ohnishi, et al.
Cancer Science|February 25, 2024
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION studyMasahiro Morise, Terufumi Kato, Shingo Matsumoto, et al.
Plos One|February 14, 2022
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis BYoshihito Nagura, Kentaro Matsuura, Etsuko Iio, et al.
Thoracic Cancer|September 13, 2022
Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective studyKei Kunimasa, Naotoshi Sugimoto, Takahisa Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 30, 2020
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitisMasanori Furukawa, Kei Moriya, Jiro Nakayama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2022
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivationTakanori Suzuki, Kentaro Matsuura, Kenji Urakabe, et al.
Journal of Gastroenterology and Hepatology|June 29, 2024
Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysisTakanori Suzuki, Kentaro Matsuura, Yuta Suzuki, et al.
Pageof 15